Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited (HKEX: 512) and its subsidiaries are a global comprehensive pharmaceutical enterprise, which is principally engaged in research, development, manufacturing and sales of pharmaceutical products, advanced medical devices, specialized pharmaceutical ingredients, biotechnology products and nutritional products. The core product portfolio cover several major therapeutic areas including respiratory and ENT, cardiovascular emergency products and advanced medical devices, bio-technology products and nutritional products. The business is structured into four major segments, namely innovative medicines and medical devices with high barriers of entry, branded drugs, pharmaceutical ingredients and products, and nutritional products.

Grand Pharmaceutical (China) Co.,Ltd., the core enterprise of the Group, has been rated as the top 40 pharmaceutical enterprises of “top 100 pharmaceutical enterprises in China” consecutively for many years. The Company has more than 8,000 knowledgeable and capable professionals, more than 60% of which are employees with master’s degree or above. The Company has engaged a number of international professional drug R&D experts from the United States, New Zealand, Australia, India and other places and domestic and foreign experts in professionals as long-term consultants, so as to continuously achieve innovation and development.

Overseas R&D members:
**Cardionovum GmbH - (Germany - clinically advanced DCB and DES cardiovascular devices) - https://cardionovum.de/
**Conavi Medical Inc. - (Canada - commercial-stage medical device company that develops image guidance technologies for use in minimally invasive cardiovascular procedures) - http://conavi.com/
**OncoSec Medical Incorporated - (NASDAQ:ONCS) - https://oncosec.com/
**Sirtex Medical Limited - (US, Australia, Germany and Singapore, working to improve outcomes in people with cancer - SIR-Spheres® Y-90) - https://www.sirtex.com/